TYME is a 3rd-line drug because of SAE, that's why Leronlimab is superior, CTC drops to zero, no SAE, enhances chemotherapy, which is still a first-line drug. Leronlimab can become a mega blockbuster. And it can be market-approved in as little as 4-5 months, amazingly. AXSM went from $ 3 to $ 100 in 12 months, so CYDY could go from $ 0.3 to $ 10 in 12 months, as NP announced. If the next two patients confirm the results of the first two, the star is born.